Advertisement

Basic Research in Cardiology

, Volume 84, Issue 5, pp 461–468 | Cite as

The effects of the propranolol enantiomers on the intracardiac electrophysiological activities of Langendorff perfused hearts

  • G. Stark
  • U. Stark
  • A. Lueger
  • H. Bertuch
  • E. Pilger
  • B. Pietsch
  • H. A. Tritthart
  • W. Lindner
Original Contributions

Summary

The optical isomers of the beta blocking agent propranolol exert beta receptor blocking as well as membrane stabilizing effects. The latter is thought to be responsible for the antiarrhythmic effect of the drug.

In this study we quantified the electrophysiological effects of both isomers of propranolol on the conduction and pacemaker system of the heart. The experiments were performed on isolated hearts using a special ECG recording and stimulation technique. To abolish isoproterenol's beta adrenergic stimulatory effect on heart rate, 30-times higher concentrations of (+)propranolol were necessary than of (−)propranolol in order to be consistent. Both isomers caused a similar and marked slowing of conduction velocity through the bundle of His and ventricular myocardium. Also, heart rate, as well as atrio-ventricular conduction velocity were significantly slowed by a concentration of 10 μM of either drug, (−)propranolol being slightly more effective. Only in the presence of (−)propranolol did significant changes of atrio-ventricular and His-bundle conduction occur at a concentration of 1 μM. During programed stimulation sinus node recovery time was more prolonged by (−)propranolol than during perfusion with (+)propranolol. The highest rate of pacing with 1∶1 conduction of the sino-atrial conduction, the atrial and ventricular myocardium was significantly depressed to a comparable degree by either isomers of propranolol. These effects appear to be primarily responsible for the antiarrhythmic effects of both isomers. Because of the minor effects of (+)propranolol on sinus- and AV-node activity, as well as on beta adrenergic receptors, this isomer may have potential clinical importance in the treatment of arrhythmias.

Key words

beta receptor propranolol enantiomers refractoriness conduction 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Barret M, Cullum VA (1968) The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmias. Br J Pharmac 34:43–55Google Scholar
  2. 2.
    Collinsworth KA, Kalman SM, Harrison DC (1974) The clinical pharmacology of lidocaine as an antiarrhythmic drug. Circulation 50:1217–1230PubMedGoogle Scholar
  3. 3.
    Coltart DJ, Meldrum S (1971) The effect of racemic propranolol and racemic practolol on the human and canine transmembrane action potential. Arch Intern Pharmacodyn 192:188–197Google Scholar
  4. 4.
    Howe R, Shanks RG (1966) Optical isomers of propranolol. Nature 210:1336–1338PubMedGoogle Scholar
  5. 5.
    Langslet A (1970) Membrane stabilizing and cardiac effects of d,1-propranolol, d-propranolol and chlorpromazine. Eur J Pharmacol 13:6–14PubMedGoogle Scholar
  6. 6.
    Lindner W, Leitner Ch, Uray G (1984) Liquid chromatographic separation of enantiomeric alkanolamine via diastereomerie tartaric acid monosters. J Chromatogr 316:605–616Google Scholar
  7. 7.
    Lubbe WF, Muller CA, Wothington M, McFadyen EL, Opie LH (1981) Influence of propranolol isomers and atenolol on myocardial cyclic AMP, high energy phosphates and vulnerability to fibrillation after coronary artery ligation in the isolated rat heart. Cardiovasc Res 15:690–699PubMedGoogle Scholar
  8. 8.
    Myers MG, Lewis PG, Reid JL, Dollery CT (1973) Cardiovascular effects of centrally administered d-, 1- and d1-propranolol in the conscious rabbit. Eur J Clin Invest 3:257–261Google Scholar
  9. 9.
    Nies AS, Shand DG (1975) Clinical pharmacology of propranolol. Circulation 52:6–15PubMedGoogle Scholar
  10. 10.
    Pruett JK, Walle T, Walle UC (1980) Propranolol effects on membrane repolarization in isolated canine Purkinje fibers: Treshold tissue content and the influence of exposure time. J Pharmacol Exp Therap 215:535–543Google Scholar
  11. 11.
    Poddu PE, Jouve R, Langlet F, Guillen JC, Fornaris M, Torresani J, Reale A (1986) Prevention of postischaemic ventricular fibrillation by long term beta adrenoceptor blockade with acubutolol in the anesthetised dog. Cardiovasc Res 20:721–726PubMedGoogle Scholar
  12. 12.
    Roman E, Ruiz F, Perez D, Hernandez J (1987) The effects of propranolol stereoisomers on nomotopic and ectopic cardiac automaticity in the heart. Chem Pathol Pharm 58:139–142Google Scholar
  13. 13.
    Saito S, Chen CM, Buchanan J, Gettes LS, Lynch MR (1978) Steady state and time dependent slowing of conduction in canine hearts. Circ Res 42:246–254PubMedGoogle Scholar
  14. 14.
    Singh SN, Di Bianco R, Davidov ME, Gottdiener JS, Johnson WI, Laddu AR, Fletchner RD (1982) Comparison of acebutolol and propranolol for treatment of chronic ventricular arrhythmia: A placebo-controlled, double blind, randomized crossover study. Circulation 65:1356–1364PubMedGoogle Scholar
  15. 15.
    Stark G, Huber U, Hofer E, Tritthart HA (1987) Continuous ECG measurements of intracardiac activity from the surface of Langendorff-perfused guinea pig hearts. Basic Res Cardiol 82:437–444PubMedGoogle Scholar
  16. 16.
    Stark G, Stark U, Tritthart HA (1989) Assessment of the conduction of the cardiac surface and stimulation technique (SST-ECG) in Langendorff perfused mammalian hearts. J Pharmacol Method, in pressGoogle Scholar
  17. 17.
    Thompson KA, Roden DM, Wood AJ, Siddoway LA, Barbey JT, Woosley RL (1984) Suppression of ventricular arrhythmias by dextro propranolol in man. Circulation 70:Supp II 1764Google Scholar
  18. 18.
    Tritthart HA (1983) Wirkspektrum von Antiarrhythmika und Betarezeptorenblockern. In: Lüderitz B (ed) Herzrhythmusstörungen. Springer-Verlag, Berlin Heidelberg New York, S 141–166Google Scholar
  19. 19.
    Tritthart HA (1988) Therapie der Erregungsbildungs- und-leitungsstörungen. In: Roskamm H, Reindell H (eds) Herzkrankheiten. Springer-Verlag, Berlin Heidelberg New York, S 660–675Google Scholar
  20. 20.
    Whitsitt LS, Lucchesi BR (1967) The cardiac beta-adrenergic receptor blocking actions of propranolol and its steroisomers. Life Sci 6:939–950PubMedGoogle Scholar
  21. 21.
    Wilde AAM, Peters RJG, Janse MJ (1988) Catecholamine release and potassium accumulation in the isolated globally ischemic rabbit heart. J Mol Cell Cardiol 20:887–896PubMedGoogle Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag 1989

Authors and Affiliations

  • G. Stark
    • 1
  • U. Stark
    • 2
  • A. Lueger
    • 2
  • H. Bertuch
    • 1
  • E. Pilger
    • 1
  • B. Pietsch
    • 1
  • H. A. Tritthart
    • 2
  • W. Lindner
    • 3
  1. 1.Department of Internal MedicineKarl-Franzens UniversityGrazAustria
  2. 2.Department of Medical Physics and BiophysicsKarl-Franzens UniversityGrazAustria
  3. 3.Institute of Pharmaceutical ChemistryKarl-Franzens UniversityGrazAustria

Personalised recommendations